Hansa Biopharma AB (HNSAN) Stock Price & Analysis
HNSAN Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- MXN 7.66B
- Enterprise Value
- MXN 4.01B
- Total Cash (Recent Filing)
- MXN 552.81M
- Total Debt (Recent Filing)
- MXN 1.03B
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Nov 11, 2026 (Est.)
- EPS Estimate
- -2.71
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strategic Partnership And Liquidity
The SERB transaction provides substantial funding ahead of potential U.S. approval and extends operating runway. This strengthens Hansa’s ability to finance commercialization, regulatory work and pipeline development while reducing immediate dependence on additional external capital.
Strong Clinical Evidence
Robust confirmatory data support imlifidase’s clinical value in highly sensitized transplant patients and strengthen the case for continued adoption. Positive PAES results also support conversion to full European approval, expanding the product’s regulatory durability.
U.S. Commercial Expansion
A defined U.S. regulatory and launch timetable creates a credible path to geographic expansion beyond the current European business. Preparing leading transplant centers and pursuing reimbursement mechanisms could support broader adoption if approval is secured.
Bears Say
Persistent Losses And Cash Burn
Deep operating losses and consistently negative cash generation show that the business has not yet reached a self-funding scale. Continued investment in commercialization and development may require substantial financing unless revenue growth and operating leverage improve materially.
Negative Equity And High Debt
A negative equity position combined with sizeable debt weakens financial resilience and restricts capital-allocation flexibility. If losses persist, Hansa may face greater refinancing pressure and fewer options to fund expansion without shareholder or creditor support.
Clinical And Adoption Hurdles
The higher observed antibody-mediated rejection rate remains a clinically important consideration even though management reported it was manageable and caused no graft losses. Addressing this issue and center-level readiness may slow physician adoption and market expansion.
Hansa Biopharma AB News
HNSAN FAQ
What is Hansa Biopharma AB’s market cap?
When is Hansa Biopharma AB’s upcoming earnings report date?
How were Hansa Biopharma AB’s earnings last quarter?
Is Hansa Biopharma AB overvalued?
Does Hansa Biopharma AB pay dividends?
What is Hansa Biopharma AB’s EPS estimate?
How many shares outstanding does Hansa Biopharma AB have?
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Hansa Biopharma AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Renée Julie Elisabet Aguiar-Lucander
- Employees
- 131
- Website
- www.hansabiopharma.com
- Address
- Scheelevägen 22, Lund, SN, 223 63, SE
Hansa Biopharma AB (HNSAN) Earnings & Revenues
HNSAN Earnings Call
Earnings Call SentimentPositive
The call contained several strong strategic and clinical positives — notably the EUR 150M out‑licensing deal (EUR 110M upfront), robust ConfideS and PAES efficacy data supporting improved kidney function and reduced dialysis dependence, and clear U.S. launch preparations with meaningful QoQ sales momentum. Offsetting these positives were near‑term commercial and financial headwinds: slight YoY revenue decline, materially higher SG&A and a widened operating loss, accounting and transition uncertainty related to the SERB transaction, and a higher observed rate of AMR that requires management despite being treatable. On balance, the transformative financing, convincing Phase III/confirmatory data, and launch readiness materially outweigh the short‑term operating and transition challenges, supporting a constructive outlook heading into the regulatory decision period.
View all MX:HNSAN earnings summaries